BillionToOne, Inc. Class A (BLLN)
NASDAQ:BLLN
Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$77.00
--
Market closed
$77.00
--
Day’s Range― - ―
52-Week Range$61.96 - $138.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)331.11K
Market Cap
$3.76B
Enterprise Value$3.21B
Total Cash (Recent Filing)$495.98M
Total Debt (Recent Filing)$108.89M
Price to Earnings (P/E)502.9
Beta0.81
Next Earnings
May 06, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding41,413,162
10 Day Avg. Volume412,805
30 Day Avg. Volume331,112
Financial Highlights & Ratios
PEG Ratio-4.71
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue10.52
Enterprise Value/Gross Profit15.40
Enterprise Value/Ebitda174.72
Forecast
1Y Price Target
$120.00Price Target Upside55.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.47
Revenue Forecast (FY)$436.52M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & GuidanceA sustained doubling of revenue in 2025 and a raised 2026 guide indicate durable commercial traction and scalable demand for UNITY tests. This underpins expanding clinical adoption, supports continued investment in sales/clinical operations, and increases visibility for multi-year growth assuming execution of payer and health-system rollouts.
Gross Margin ExpansionSharp improvement in gross margins reflects stronger ASPs and lower COGS per test, implying improving unit economics and pricing power. Higher and sustained gross margins give the company structural flexibility to fund sales expansion and R&D while maintaining operating profitability as volume scales.
Balance Sheet & Cash GenerationA robust cash position and materially de‑levered balance sheet provide multi-year runway to fund commercialization, evidence generation, and integration projects without reliance on dilutive capital. Positive operating cash flow signals improving cash conversion and reduces financial vulnerability during scaling.
Bears Say
Reimbursement Risk For OncologyOncology upside depends materially on MolDX/CMS coverage for Northstar Response; lack of confirmed reimbursement constrains revenue visibility and adoption at scale. Delayed or negative coverage would slow oncology volume growth and limit realization of the product's revenue and margin potential over the medium term.
Rising Operating ExpensesRapid commercial and R&D spending to scale the field force and product pipeline increases structural operating leverage risk. If revenue growth or margin mix underperforms, sustained elevated SG&A/R&D could compress profits and cash generation, making consistent long‑term profitability contingent on disciplined cost control and execution.
Provider Awareness & Competitive BarriersA large awareness gap and entrenched incumbent relationships create a multi‑year commercialization challenge: adoption requires education, payer alignment, and EMR integrations. These structural sales friction points lengthen sales cycles and raise the execution bar for sustained share gains in prenatal and oncology markets.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $138.70 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $3.76B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is May 06, 2026 which is in 6 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on Mar 04, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate is 0.03.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,413,162 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.11 in its last earnings report, beating expectations of $0.06. Following the earnings report the stock price went down -10.714%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.00 (55.84% Upside)
$120.00 (55.84% Upside)
Blogger Sentiment
Bullish
BLLN Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Fundamentals
Return on Equity
1.30%
Trailing 12-Months
Asset Growth
109.45%
Trailing 12-Months
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and financial story: exceptional top-line growth (100% YoY), margin expansion (71% gross margin, GAAP profitability), robust cash balance, multiple product launches, and payer wins including UnitedHealthcare. Key near-term risks include reimbursement timing for Northstar Response (MolDX/CMS), rising operating expenses as the company scales, oncology being a small absolute base despite rapid percentage growth, and execution dependencies for health-system integrations and broader provider awareness. Overall, the company emphasized continued momentum and conservative guidance that still leaves multiple upside catalysts unmodeled.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$120.00
▲(55.84% Upside)
Ownership Overview
34.60% Insiders
4.89% Mutual Funds
0.91% Other Institutional Investors
58.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---